EUVIMEDEUVIMED entdecken
Crossref

Diagnostic Performance of 99 mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism

Ante Mandic iD, Ivana Kraljevic, Tanja Skoric Polovina, Karin Zibar Tomsic, Tina Dusek, Annemarie Balasko, Mirsala Solak, Darko Kastelan iD

Nuklearmedizin - NuclearMedicine · 01.10.2025 · 64 (05) · 308-312

DOI: 10.1055/a-2694-8426 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.10.2025. Verfasst von Ante Mandic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina. Hauptthemen laut MEDLINE: Technetium Tc 99m Sestamibi, Hyperparathyroidism, Primary, Choline, Positron Emission Tomography Computed Tomography. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to assess the diagnostic performance of 99mTc-sestamibi SPECT/CT and 18F-choline PET/CT in detecting hyperfunctioning parathyroid glands in patients undergoing surgery for primary hyperparathyroidism (PHPT). A retrospective analysis was conducted on patients who underwent PHPT-related surgery between April 2019 and May 2022. The study focused on patients undergoing either 99mTc-sestamibi SPECT/CT (81 patients) or 18F-choline PET/CT (33 patients) scans before surgery to pinpoint hyperfunctioning parathyroid gland(s). In the majority of patients, 18F-choline PET/CT was performed after negative or inconclusive findings on 99mTc-sestamibi SPECT/CT. Pathohistological reports were utilized as the reference standard for evaluating the accuracy of the imaging findings. The study encompassed 83 patients (70 females, 84.3 %) with an average age of 57.2 years (24–80 years). The pathohistological analysis identified a total of 98 glands. In a per-lesion analysis, the detection rate of 99mTc-sestamibi SPECT/CT was 57 % (95 % CI 45.3–68.1), while the detection rate of 18F-choline PET/CT was 90.3 % (95 % CI 74.3–98.0). The results of our study showed the significant usefulness of 18F-choline PET/CT in patients with negative or inconclusive results of 99mTc-sestamibi SPECT/CT in accurately locating hyperfunctioning parathyroid glands in PHPT patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technetium Tc 99m SestamibiHyperparathyroidism, PrimaryCholinePositron Emission Tomography Computed TomographyParathyroid GlandsHumansMiddle AgedFemaleMaleAdultAgedAged, 80 and overRetrospective StudiesYoung Adult

Substanzen

Technetium Tc 99m SestamibiCholine

Autor:innen und Institutionen

  • Department of Endocrinology, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
  • University of Zagreb School of Medicine, Zagreb, Croatia.
  • Department of Endocrinology, University Hospital Centre Zagreb, Zagreb, Croatia.

ORCID-Profile: Ante Mandic, Darko Kastelan

Zitieren

APA

Mandic, A., Kraljevic, I., Skoric Polovina, T., Zibar Tomsic, K., Dusek, T., Balasko, A., Solak, M., & Kastelan, D. (2025). Diagnostic Performance of 99 mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism. Nuklearmedizin - NuclearMedicine, 64(05), 308-312. https://doi.org/10.1055/a-2694-8426

Vancouver

Mandic A, Kraljevic I, Skoric Polovina T, Zibar Tomsic K, Dusek T, Balasko A, et al. Diagnostic Performance of 99 mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism. Nuklearmedizin - NuclearMedicine. 2025;64(05):308-312. doi:10.1055/a-2694-8426

BibTeX
@article{Mandic2025,
  author = {Mandic, Ante and Kraljevic, Ivana and Skoric Polovina, Tanja and Zibar Tomsic, Karin and Dusek, Tina and Balasko, Annemarie and Solak, Mirsala and Kastelan, Darko},
  title = {Diagnostic Performance of 99 mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2025},
  volume = {64},
  number = {05},
  pages = {308--312},
  doi = {10.1055/a-2694-8426}
}
Kostenlos starten →